Phase IIb, a double-blind, placebo-controlled clinical trial to investigate the safety and efficacy of MDMA-assisted psychotherapy for Alcohol Use Disorder

This trial builds on the results of a Phase I study from the same research group. In the open-label study, MDMA-assisted psychotherapy was well-tolerated and safe to use. The average consumption of alcohol nine months later was 18.7 units, versus 130.6 units before the detox.

Awakn Life Sciences is planning to conduct a Phase II study exploring the safety and efficacy of MDMA-assisted psychotherapy for Alcohol Use Disorder (AUD).

Topic Addiction Alcohol Use Disorder
Compound MDMA
Country United Kingdom
Visit trial
Status Planned
Results Published No
Start date 31 January 2022
End date 31 January 2022
Chance of happening 69%
Phase Phase II
Design Open
Type Interventional
Generation First
Participants 20
Sex All
Age 18- 99
Therapy Yes

Trial Details



NCT Number

Sponsors & Collaborators

Awakn Life Sciences
AWAKN Life Sciences aims to bring psychedelics therapy to the UK. Under this company fall three arms; psychedelic research, clinic platform, and practitioner training.

Imperial College London
The Centre for Psychedelic Research studies the action (in the brain) and clinical use of psychedelics, with a focus on depression.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.